Soliris - 2007 FDA approvals

Drug: Soliris (eculizumab)
Indication: Paroxysmal nocturnal hemoglobinuria
Company: Alexion
Approval Date: March 16, 2007

Scoop: Soliris is a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria--a disease in which the immune system attacks the body's own red blood cells.

More news:
Alexion's eculizumab succeeds in Phase III. Report
Alexion shares surge on eculizumab data. Report

Soliris - 2007 FDA approvals
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i